Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03058224
Other study ID # IGN-ES001-CR01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 16, 2017
Est. completion date December 8, 2017

Study information

Verified date August 2018
Source IgNova GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled exploratory trial to investigate efficacy and safety of food supplement IGN-ES001 in patients with chronic widespread pain (CWP) with or without fibromyalgia (FM).


Description:

Patients will perform five scheduled on-site visits and five phone calls:

- Screening visit, V1 (Day -10 to -7), informed consent

- Baseline visit, V2 (Day 1), randomization, treatment start

- Phone call, V3 (Day 4 ± 1)

- Phone call, V4 (Day 8 ± 3)

- Phone call, V5 (Day 15 ± 3)

- On-site visit, V6 (Day 22 ± 3)

- Phone call, V7 (Day 29 ± 3)

- Phone call, V8 (Day 36 ± 3)

- On-site visit, V9 (Day 43 + 3), treatment end

- Follow-up on-site visit, V10 (Day 50 + 7, or 7 + 7 days after EDV).

In addition, patients may be asked to return to the trial site between scheduled visits for assessment of safety data (unscheduled visits).

The maximum duration of treatment for the individual patient will be 46 days (including allowed visit window deviation). The maximum duration of trial participation for the individual patient will be 67 days.


Recruitment information / eligibility

Status Completed
Enrollment 230
Est. completion date December 8, 2017
Est. primary completion date November 30, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Male or female out-patient = 18 years and = 70 years of age.

2. Patient willing and able (e.g. mental and physical condition) to participate in all aspects of the trial, including use of investigational product, subjective completion of diaries and questionnaires, attending scheduled visits, completing telephone interviews, and compliant with protocol requirements as evidenced by providing signed writteninformed consent.

3. History of chronic widespread pain (for at least three months prior to visit V1 (screening)).

4. a.) For FM patients: Widespread Pain Index (WPI) = 7 and Symptom Severity (SS) = 5 or WPI 3-6 and SS = 9 (original preliminary fibromyalgia criteria of the American College of Rheumatology (ACR) 2010).

b.) For non-FM CWP patients: WPI = 3-6 and SS = 5-8 (modified from the preliminary fibromyalgia criteria of the ACR 2010).

5. Use of prior and concomitant medications/ therapies (if not excluded, see exclusion criteria no 6 and no 7), non-pharmacological therapies and lifestyle habits (e.g. diet changes, Ramadan participation, etc.) that could influence the efficacy assessments must have been stable for at least 30 days prior to visit V1 (screening) and are anticipated to be at a stable regimen throughout the trial until visit V9.

6. Patient has negative urine test at screening visit V1 for the following drugs of abuse:

1. Amphetamine

2. Cocaine

3. Metamphetamine

4. Morphine

5. Tetrahydrocannabinol

7. Female patient is surgically sterile (i.e. bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or at least two years postmenopausal or, if of childbearing potential, she is sexually abstinent or agrees to practice adequate contraceptive measures (hormonal contraceptives, intrauterine device, double-barrier method).

8. Patient must have completed at least 6 screening phase diary pages satisfactorily within the past 7 days before visit V2.

9. Median pain NRS must be = 4 in at least 1 out of the 6 pain qualities and = 4 in overall pain assessment. The median will be calculated from the last 7 days before visit V2 (baseline) and will serve as baseline value.

If all inclusion criteria are fulfilled (and none of the exclusion criteria below), the patient will be randomized at visit V2 and continues in the trial. Otherwise the patient will be excluded from trial participation.

Exclusion Criteria:

1. Patients without a basic and stable CWP therapy which started at least 30 days before V1 (screening) i.e. treatment-naive patients, first diagnosis.

2. Known allergy or intolerance to egg or egg constituents.

3. History of or currently active malignancy except for malignancies that were successfully treated and have had no recurrence within 5 years before screening visit V1.

4. Known, uncontrolled endocrine disorders, such as hypothyroidism (TSH and free T4), and diabetes mellitus (HbA1c).

5. Known severe hepatic, renal, respiratory, hematologic, neurologic, infectious, or immunologic disease, unstable cardiovascular disease, or any other medical or psychiatric condition that, in the judgment of the investigator, would make the patient inappropriate for participation in this trial.

6. Immune response modulating medication/ therapy e.g. systemic corticosteroids, antibodies other than IP (investigational product) from a period starting 90 days before visit V1 (screening).

7. WHO step-II and step-III opioids (except occasional use of codeine as cough medication) from a period starting 60 days before visit V1 (screening).

8. Intractable vomiting likely to significantly influence gastrointestinal (GI) investigational product presence.

9. Surgery within 60 days before visit V1 (screening) or anticipated or scheduled for the next nine weeks after visit V1 (screening).

10. Vaccination from a period starting 30 days prior to visit V1 (screening).

11. Known liver disease or evidence of impaired hepatic function (total bilirubin, aspartate aminotransferase [ASAT], alanine transaminase [ALAT], gamma-glutamyltransferase [GGT], or alkaline phosphatase [AP] > 3 times the upper limit of normal).

12. Known kidney disease or evidence of impaired renal function, i.e. estimated glomerular filtration rate (eGFR) based on serum creatinine < 60 mL/min as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.

13. Pregnancy or breastfeeding.

14. Known severe psychiatric illness (e.g. schizophrenia, major depression, anxiety disorder, obsessive compulsive disorder, panic disorder, social phobia, post-traumatic stress) or personality disorder (e.g. borderline personality). Obvious suicide risk.

15. Current and/ or history of known or suspected drug or substance abuse including alcohol abuse within five years before visit V1 (screening) as stated by the patient and/ or withdrawal symptoms.

16. Previous enrolment in this trial, or participation in any other studies involving investigational products, simultaneously or within six months prior to be screened for this trial (visit V1).

17. Persons committed to an institution by virtue of an order issued either by the judicial or other authorities.

18. Employee of the investigator or trial site, with direct involvement in the proposed trial or other studies under the direction of that investigator or trial site, as well as family members of the employees or the investigators.

19. Patients unable or unwilling to include yoghurt or ayran into their daily diet.

20. Severe diarrhea.

Study Design


Intervention

Drug:
IGN-ES001
Only active product will be compared with placebo as described in Arms and Interventions.
Parol 500 mg Tablets (acetaminophen)
Analgesic Rescue Medication

Locations

Country Name City State
Turkey Çukurova University School of Medicine Adana
Turkey Akdeniz University School of Medicine Antalya
Turkey Adnan Menderes University School of Medicine Aydin
Turkey Uludag University School of Medicine Bursa
Turkey Onsekiz Mart University School of Medicine Çanakkale
Turkey Trakya University School of Medicine Edirne
Turkey Gaziantep University School of Medicine Gaziantep
Turkey Bezmialem Vakif University School of Medicine Istanbul
Turkey Istanbul Physical Treatment and Rehabilitation Training and Research Hospital Istanbul
Turkey Istanbul University Cerrahpasa School of Medicine Istanbul
Turkey Istanbul University Istanbul School of Medicine Istanbul
Turkey Maltepe University School of Medicine Istanbul
Turkey Marmara University Pendik Training and Research Hospital Istanbul
Turkey Sisli Florence Nighingale Hospital Istanbul
Turkey Sisli Hamidiye Etfal Training and Research Hospital Istanbul
Turkey Izmir Medical Park Hospital Izmir
Turkey Erciyes UNiversity School of Medicine Kayseri
Turkey Necmettin Erbakan University School of Medicine Konya
Turkey Sakarya University School Of Medicine Korucuk Training and Research Hospital Sakarya
Turkey Cumhuriyet University School of Medicine Sivas
Turkey Namik Kemal University School of Medicine Tekirdag
Turkey Karadeniz Technical University School of Medicine Trabzon
Turkey Bülent Ecevit University School of Medicine Zonguldak

Sponsors (6)

Lead Sponsor Collaborator
IgNova GmbH CenTrial GmbH, idv Data Analysis and Study Planning, Klinar CRO, Pharmasolutions4U, SCOPE International AG

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain, final percent changes from baseline (based on diary), univariate analysis The overall pain improvement will be assessed by means of the percent changes from baseline (Visit 2) to end of treatment visit (Visit 9). Percent changes are preferred to raw changes due to their implicit adjustment for baseline differences in the case of proportional decrease. The baseline pain value will be calculated as mean overall pain of the last seven-day time period of the screening phase from Day -7 to Day -1. Minimum the last 6 out of 7 days prior to baseline visit V2 must be documented. The final pain value will be calculated as mean overall pain of the last seven-day time period prior to the end of the adjunctive treatment period from Day 36 to Day 42. Six Weeks
Primary Pain, final percent changes from baseline (based on diary), multivariate analysis In addition to the univariate analysis of the overall pain score, a correlation-sensitive multidimensional approach will be performed with respect to the two major pain activity levels:
Pain at rest (sum score of three locations), percent change from baseline
Pain perceived during physical strain (sum score of three locations), percent change from baseline
Six Weeks
Primary Pain, final responder (based on diary) Responders will be defined as patients with a percent decrease from baseline of the overall pain score by at least 30%. This is a recommended benchmark for a "clinically meaningful improvement" (Farrar et al.), and provides robustness in case of proportional pain decrease (independency from baseline pain level). Tubach et al. (2012) defined a percent decrease of 20% as minimal clinically important change. Thus, the recommendation of Farrar et al. is regarded as optimum choice for a clinically meaningful responder definition. Six Weeks
Secondary Responder* rate, alternative definition (based on diary) Six Weeks
Secondary Change in Fibromyalgia Impact Questionnaire Revised version (FIQ-R) score from baseline (visit V2) Six Weeks
Secondary Change in Short-Form-36 version 2 Quality-of-Life questionnaire (SF-36v2TM) score from baseline (visit V2) Six Weeks
Secondary Change in Medical Outcomes Study Sleep Scale (MOS-SS) score from baseline (visit V2) Six Weeks
Secondary Change in Fatigue Severity Scale (FSS) score from baseline (visit V2) Six Weeks
Secondary Patient's Global Impression of Change (PCIG) Questionnaire "The patients will rate their change in the overall status "since the start of the study, my overall status is" on a scale ranging from 1 (= very much improved) to 7 (= very much worse). Patients will complete the PGIC questionnaire at visit 9 (or at Early Discontinuation Visit) covering the whole 6-week treatment period from baseline visit 2." Six Weeks
Secondary Consumption of rescue medication Six Weeks
Secondary Time to first rescue medication (days) Dependent to the timeframe of the first rescue medication from first investigational product intake following baseline visit 2 through study completion, an average of six weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05659862 - Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT03042728 - Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program N/A
Recruiting NCT06097091 - Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia N/A
Recruiting NCT04554784 - Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia N/A
Completed NCT03300635 - Metabolism, Muscle Function and Psychological Factors in Fibromyalgia N/A
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT03227952 - Sensory Stimulation in Fibromyalgia N/A
Completed NCT03166995 - Postural Exercises in Women With Fibromyalgia N/A
Recruiting NCT06237595 - Vagus Nerve Stimulation in Fibromyalgia N/A
Completed NCT01888640 - Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST) N/A
Completed NCT03641495 - Pain Education and Therapeutic Exercise for Fibromyalgia N/A
Recruiting NCT05581628 - FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
Active, not recruiting NCT05128162 - Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia Phase 2
Completed NCT04674878 - Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia N/A
Active, not recruiting NCT04084795 - Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia N/A
Completed NCT03129906 - Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients N/A
Completed NCT05058911 - Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia N/A
Recruiting NCT04571853 - New Educational Tool for FM N/A
Recruiting NCT04571528 - Effectiveness of VIRTUAL FIBROWALK STUDY N/A